Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 10—October 2024
Research

Virulence of Burkholderia pseudomallei ATS2021 Unintentionally Imported to United States in Aromatherapy Spray

On This Page
Materials And Methods
Results
Discussion
Suggested Citation
Figures
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Tables
Table
Downloads
Appendix 1
Appendix 2
RIS [TXT - 2 KB]
Article Metrics
Metric Details
Author affiliations: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA (C.K. Cote, K.D. Mlynek, C.P. Klimko, S.S. Biryukov, S. Mou, M. Hunter, N.O. Rill, J.L. Dankmeyer, J.A. Miller, Y. Talyansky, M.L. Davies, J.M. Meinig, S.A. Halasohoris, A.M. Gray, J.L. Spencer, A.L. Babyak, M.K. Hourihan, B.J. Curry, R.G. Toothman, S.I. Ruiz, X. Zeng, K.M. Ricks, T.L. Clements, C.E. Douglas, S. Ravulapalli, C.P. Stefan, C.J. Shoemaker, J. Qiu, J.A. Bozue, N.A. Twenhafel, D. DeShazer); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.G. Elrod, J.E. Gee, Z.P. Weiner)

Suggested citation for this article

Abstract

In the United States in 2021, an outbreak of 4 cases of Burkholderia pseudomallei, the etiologic agent of melioidosis and a Tier One Select Agent (potential for deliberate misuse and subsequent harm), resulted in 2 deaths. The causative strain, B. pseudomallei ATS2021, was unintentionally imported into the United States in an aromatherapy spray manufactured in India. By analyzing virulence, we established that ATS2021 represents a virulent strain of B. pseudomallei capable of robust formation of biofilm at physiologic temperatures that may contribute to virulence. By using mouse melioidosis models, we determined median lethal dose estimates and analyzed the bacteriologic and histopathologic characters of the organism, particularly the potential neurologic pathogenesis that is probably associated with the bimABm allele identified in B. pseudomallei strain ATS2021. Our data, combined with previous case reports and the identification of endemic B. pseudomalleistrains in Mississippi, support the concept that melioidosis is emerging in the United States.

In the United States, melioidosis is an emerging infectious disease caused by Burkholderia pseudomallei (1,2). In melioidosis-endemic areas, the bacterium causes pneumonia and fatal bacteremia with diverse mortality rates that depend on the standard of care provided, patient risk factors (e.g., diabetes), and extent and location of the infection (3,4). Melioidosis clinical manifestation ranges from asymptomatic to acute pulmonary severe illness or chronic infection (1). In a subset of patients (1.5%–5%), B. pseudomallei infection leads to serious neurologic melioidosis (5,6). Clinical signs/symptoms are fever, headache, seizures, unilateral weakness, paralysis, encephalomyelitis, and brain abscesses. Treatment duration is typically >6 months and includes an intravenous intensive phase and an oral eradication phase (7). Most cases of neurologic melioidosis are reported in the melioidosis-endemic areas of Australia and India (8–10).

In 2021, melioidosis was confirmed in 4 patients in the United States who had not traveled internationally (11). Whole-genome sequencing and epidemiologic investigations linked the clonal isolates of B. pseudomallei ATS2021 from all 4 patients to an aromatherapy spray imported from India. Neurologic melioidosis affected 2 of the patients; 1 died and 1 experienced long-term sequelae (11). Of the 2 cases of melioidosis that were not shown to have neurologic involvement, 1 was fatal and the other patient recovered. In addition, a pet raccoon that had direct contact with the contaminated spray exhibited neurologic signs approximately 2 weeks after contact with the contaminated spray and 3 days before death. Although viable bacteria were not recovered from the carcass, tissue samples were positive by PCR for B. pseudomallei DNA and provide support that the likely cause of death was neurologic (12).

Inhaled B. pseudomallei can enter the central nervous system (CNS) through several portals (13–15). Previous studies in mice demonstrated colonization at the nasal mucosa-associated lymphoid tissue and the olfactory epithelium (16). Tracking B. pseudomallei after intranasal exposure demonstrates that the bacterium crosses the respiratory epithelium, but invasion requires that the olfactory epithelium be previously damaged (16). Neurologic disease is associated with the Burkholderia intracellular motility factor A (BimA) (17,18), a protein that is essential for actin-based motility, enabling intracellular movement and evasion of the immune system (18). Although all B. pseudomallei strains possess bimA, a subset encodes a variant gene (bimABm) that is 95% homologous to the gene in the closely related Burkholderia mallei, which correlates with neurologic involvement (8,18). In our study, we characterized B. pseudomallei ATS2021 and laid the groundwork for using that strain to test medical countermeasures against melioidosis.

Materials And Methods

Growth Curve Determinations

B. pseudomallei strains were grown in either Luria broth with 4% glycerol (LBG), 4% glycerol, 1% tryptone, 5% NaCl broth (GTB), M9 (minimal medium) + 2 % glucose, (M9G), or M9G + 0.5% casamino acids (M9GC). We resuspended strains from an overnight broth culture to a 600 nm optical density (OD600) of 0.5 in brain–heart infusion broth. We diluted suspensions 1:10 into a 96-well microtiter plate, grew them in a Spark (Tecan Group, https://www.tecan.com) microplate reader shaken at 37°C for ≈36 hours, and measured OD600 hourly. We obtained data by subtracting the value of the respective medium-only control from the measured OD600.

Biofilm Assay

We used crystal violet staining to measure biofilm. We resuspended B. pseudomallei overnight broth cultures to an OD600 of ≈0.2 in phosphate-buffered saline (PBS) and diluted the bacterial suspensions 1:10 into LBG, GTB, M9G, or M9GC in CoStar polystyrene 96-well plates, incubated at room temperature or 37°C for 24 or 48 hours. Before staining, we measured the OD600, after which we aspirated plates, washed 3 times with PBS to remove planktonic cells, and fixed with 100% ethanol for 30 minutes at room temperature. After fixing the samples in ethanol, we added 0.1% (wt/vol) crystal violet to each well for 15 minutes, washed 3 times with PBS, after which we solubilized the remaining stain in 33% acetic acid. To quantify staining as an indicator of biofilm formation, we measured the OD600. When necessary, we diluted samples in 33% acetic acid to ensure that readings were within linear range. We averaged >3 technical replicates in each experiment. Data reported are the result of >4 individual experiments.

Mouse Exposure to Aerosolized Bacteria

We started cultures by inoculating GTB with frozen bacterial stocks and growing them at 37°C while shaken at 200 rpm. We estimated bacterial concentrations by 620 nm OD (OD620) and then determined CFU by growing B. pseudomallei on sheep blood agar plates (Remel; Thermo Fisher Scientific, https://www.thermofisher.com). We exposed mice to aerosolized B. pseudomallei ATS2021 at increasing concentrations in a whole-body aerosol exposure chamber equipped with the automated Biaera particle generator (19). The small-particle aerosol size diameter is ≈1–3 μm. To estimate inhaled doses, we serially diluted samples collected by using an all-glass impinger onto sheep blood agar plates (20).

Mouse 50% Lethal Dose Determinations and Bacterial Burden

At the time of exposure to aerosolized B. pseudomallei, female C57BL/6 and BALB/c mice (Charles River Laboratory) were 7–9 weeks of age. We exposed 48 C57BL/6 mice to 5 aerosolized doses of B. pseudomallei (Table). To calculate the 50% lethal dose (LD50), we observed a subset of those mice for clinical signs for 60 days after exposure. We serially euthanized other mice for histopathologic and bacteriologic analyses. We also determined LD50 for BALB/c mice.

Start// Capsule Detection

We detected B. pseudomallei capsular polysaccharide (CPS) in brain homogenates by using an antigen capture immunoassay developed on the Magpix platform (Thermo Fisher Scientific) We coupled Burkholderia CPS antibody, 4C4 (21), to magnetic beads by using a Luminex xMap kit and biotinylated by using an EZ-link Sulfo-NHS-LC-Biotin kit (Thermo Fisher Scientific). We added 4C4-coupled beads (2,500 beads/well), and 50 μL of study samples diluted 1:20 in 5% skim milk in PBS with 0.5% Tween-20 (mixture called SM) to white, round-bottom 96-well plates and incubated for 1 hour with shaking. We washed the wells 3 times with 100 μL of PBS-T (PBS with Tween 20) before adding 50 μL of 4 μg/mL of biotinylated 4C4 in SM. After incubating the wells for 1 hour, we washed them before adding 50 μL of 10 μg/mL streptavidin phycoerythrin in SM. After the wells were incubated for 30 minutes, we washed the beads, resuspended then in 100 μL of PBS-T, and read them by using the Magpix instrument. We considered samples with a median fluorescent intensity 2-fold over naive brain homogenate to be positive.

Histopathologic Analyses

We examined a subset of mice histopathologically (Appendix 1 Table 1). We performed necropsies and processed the tissues after they had been in 10% buffered formalin for 21 days. We produced tissue blocks and slides and stained them with hematoxylin and eosin. We performed immunohistochemistry (IHC) on select animals by using the BOND RX Automated Stainer (Leica Biosystems, https://www.leicabiosystems.com). We used a rabbit polyclonal Burkholderia antibody (antibody no. 351; US Army Medical Research Institute of Infectious Diseases) at a dilution of 1:5,000. We counterstained the sections with hematoxylin and applied coverslips.

RNA Extraction and Nanostring Data Collection

We inactivated all brain homogenates with a 3:1 ratio of TRIzol LS (Thermo Fisher Scientific) and extracted total RNA as previously reported (22). We collected host gene expression data by using the nCounter mouse Neuroinflammation Panel on the SPRINT Profiler platform (NanoString Inc, https://nanostring.com). The panel consists of 770 genes spanning 23 neuroinflammation pathways and processes. In brief, we added 70 μL of hybridization buffer to the reporter code set to make a master mixture. We added 8 μL of the master mixture to 50 ng of extracted host RNA and 2 μL of the capture code set, incubated it at 65°C for 17 hours, and then incubated at 4°C until the samples were placed on a NanoString SPRINT Profiler and total fluorescent counts corresponding to target binding were collected. We extracted gene expression analysis and cell profiling data from Nanostring RCC files and analyzed by using the ROSALIND Bioinformatics suite (https://rosalind.bio). We generated normalized counts by using criteria provided by NanoString. ROSALIND follows the nCounter Advanced Analysis protocol (NanoString) of dividing counts within a lane by the geometric mean of the normalizer probes from the same lane. Housekeeping probes to be used for normalization are selected based on the geNorm algorithm as implemented in the NormqPCR R library1 (23). Unless otherwise noted, we based significance of differentially expressed genes on them passing a filter greater than ±1.5-fold linear threshold and an adjusted p<0.05 relative to brain homogenates from an unchallenged mouse group. We based cell profiling data for oligodendrocytes on abundance scores provided by the ROSALIND NanoString Cell Type Profiling Module. We performed statistical analyses and graphing for host gene expression on Graphpad Prism 9.4.0 (https://www.graphpad.com).

Statistical Analyses

We analyzed biofilm data analyzed by using a linear mixed effects model implemented in the GLIMMIX procedure of SAS version 9.4 (SAS Institute Inc., https://www.sas.com). We did not apply multiplicity adjustment. We estimated LD50 under a probit model with log10 transformation of the dose variable and obtained LD50 pairwise comparisons by using nonlinear mixed model on the log10 dose scale. We estimated median time to death or euthanasia in accordance with early endpoint euthanasia criteria and accompanying confidence limits, mean time to death, and SE by using Kaplan-Meier survival methods. We determined correlation between in vitro biofilm production and in vivo virulence by using Spearman rank order analyses. We performed analysis in SAS version 9.4.

Results

Genetic Analyses and Molecular Virulence Determinants of ATS2021

Figure 1

Phylogenetic tree based on bimABp and bimABm alleles from strains of Burkholderia pseudomallei, B. mallei, and B. humptydooensis, showing location of B. mallei ATS2021 (arrow), the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. NGPhylogeny.fr (12) was used to build the tree in “A la Carte” mode, and it used MUSCLE for multiple alignment, Gblocks for automatic alignment curation (https://NGphylogeny.fr for both), PhyML-SMS (https://www.atgc-montpellier.fr) for tree inference, and exported to the Interactive Tree Of Life (iTOL; https://itol.embl.de) for display and manipulation. B. pseudomallei strains were isolated in Thailand (T), Australia (A), India (I) and Papua New Guinea (P). Scale bar indicates number of substitutions per site. bimA, Burkholderia intracellular motility factor A.

Figure 1. Phylogenetic tree based on bimABp and bimABm alleles from strains of Burkholderia pseudomallei, B. mallei, and B. humptydooensis,...

The ATS2021 whole-genome shotgun sequencing project was available in GenBank (accession no. JASCQT000000000.1). We examined the genetic sequence of known B. pseudomallei surface-associated virulence determinants, including the 6-deoxyheptan CPS (24), the lipopolysaccharide O-antigen (25), and the cluster 1 type 6 secretion system (26). Those gene clusters exhibited ≈99% identity with the corresponding gene clusters in the prototypic strain B. pseudomallei K96243 (27). In addition, immunoblot analysis with specific antibodies demonstrated the production of CPS and type A lipopolysaccharide O-antigen when ATS2021 was grown in vitro (data not shown). Petras et al. recently revealed that ATS2021 harbors a bimA gene that closely resembles the bimA gene found in B. mallei, the etiologic agent of glanders (12). The bimA gene encodes a trimeric autotransported protein that mediates actin-based motility in infected host cells (28). Most B. pseudomallei strains from environmental or clinical sources contain the bimABp allele, but a relatively small number of strains possess the bimABm allele and are often isolated from patients with neurologic melioidosis (17,18,29,30). The presence of the bimABm allele is thought to exacerbate neurologic melioidosis by increasing rapidity of bacterial dissemination to various tissues and persistence in phagocytic cells (29). The phylogenetic tree is based on the unique bimABm alleles deposited in publicly available draft and complete genome sequence databases (Figure 1). The B. pseudomallei bimABm sequences are all derived from strains originating in Australia, Papua New Guinea, and India, differing from each primarily in the region encoding the proline-rich domain (28,30). The ATS2021 bimA (Figure 1, solid arrow) groups within the bimABm branch of the tree. B. pseudomallei strains with the bimABm allele have also been described in Sri Lanka (31), but the sequences of those isolates have not been made publicly available. Of note, 2 environmental isolates of Burkholderia humptydooensis, MSMB 43 and MSMB121, harbor genes that are closely related to the bimABm alleles in B. mallei and B. pseudomallei (32) (Figure 1). To demonstrate the sequence differences between the bimABp and bimABm alleles, we included 3 representative bimABp alleles from K96243, 1026b, and 576 (Figure 1).

ATS2021 Robust Biofilm

Figure 2

Biofilm formation of Burkholderia pseudomallei strains ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021, and K96243 under multiple test conditions. Biofilm formation of both strains was assessed by crystal violet staining as measured by OD600. A) One day at room temperature; B) 1 day at 37°C; C) 2 days at room temperature; D) 2 days at 37°C. Error bars represent the SEs from mean values determined from 3 separate assays. p values determined by linear mixed effects model. M9G, M9 + glucose; M9GC, 0.2% glucose to M9 and casamino acids; OD600, optical density at 600 nm.

Figure 2. Biofilm formation of Burkholderia pseudomalleistrains ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021, and K96243...

Figure 3

Biofilm production for Burkholderia pseudomallei strain ATS2021, the causative strain in an outbreak of 4 cases, 2 of them fatal, in the United States in 2021, in relation to other previously characterized B. pseudomallei clinical isolates. Biofilm formation of bacterial strains was assessed by crystal violet staining as measured by OD600. Biofilm was allowed to form after static growth in LB+4% glycerol for 1 day at 37°C. Clinical isolates used in this assay originated from Thailand (red bars) or Australia (green bars). Error bars represent the SEs from mean values determined from 4 independent assays. ATS2021 formed significantly more biofilm under these conditions compared to all isolates except MSHR5848 as determined by a linear mixed effects model. OD600, optical density at 600 nm.

Figure 3. Biofilm production for Burkholderia pseudomalleistrain ATS2021, the causative strain in an outbreak of 4 cases, 2 of them fatal, in the United States in 2021, in relation to...

We compared growth of K96243 and ATS2021 in several types of rich or defined media to assess differences with nutritional requirements and observed no differences in growth between the 2 strains (Appendix 2 Figure). We measured the ability of K96243 and ATS2021 to produce biofilm by using different growth media, incubation times, and temperatures. Low-level biofilm was detected for both strains after 1 day at room temperature (Figure 2). However, after 2 days at room temperature, levels of biofilm were higher for K96243 and ATS2021, especially in the rich media (LBG and GTB). The difference in biofilm formation was greater after incubation at 37°C; ATS2021 produced more biofilm than K96243. To determine if the increased formation at 37°C was specific to ATS2021, we tested biofilm formation in B. pseudomallei strains that accounted for the previously described strain panel (33). The clinical isolates formed variable biofilms, but ATS2021 produced substantially more biofilm at 37°C than the other strains, except MSHR5848 (Figure 3). Those differences were not observed when the bacteria were grown at room temperature (Figure 2; data not shown for all bacteria). Retrospective analyses demonstrated a negative correlation between in vitro biofilm formation and in vivo virulence in mice after exposure to aerosolized B. pseudomallei (Spearman correlation −0.70 and p = 0.017 for BALB/c mice; Spearman correlation −0.63 and p = 0.038 for C57BL/6 mice). Those analyses did not reveal statistically significant correlations between in vitro biofilm formation and in vivo virulence in mice after intraperitoneal injection of B. pseudomallei.

LD50 Determinations in Mice

Figure 4

Kaplan-Meier survival plots calculated for C57BL/6 mice exposed to aerosolized Burkholderia pseudomallei ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. A) Survival after 21 days; B) survival after 60 days. N = 10 per aerosolized dose of B. pseudomallei. The day 21 survival rates from highest to lowest calculated inhaled dose of B. pseudomallei ATS2021 (4,490 CFU, 1,150 CFU, 107 CFU, 13 CFU, 1 CFU) as depicted in panel A are 0/10, 0/10, 4/10, 8/10, and 10/10. The day 60 survival rates from highest to lowest calculated inhaled dose of B. pseudomallei ATS2021 as depicted in panel B are 0/10, 0/10, 0/10, 3/10, and 9/10.

Figure 4. Kaplan-Meier survival plots calculated for C57BL/6 mice exposed to aerosolized Burkholderia pseudomalleiATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the...

Figure 5

Kaplan-Meier survival plots calculated for BALB/c mice exposed to aerosolized Burkholderia pseudomallei ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. A) Survival after 21 days; B) survival after 60 days. N = 10 per aerosolized dose of B. pseudomallei. The day 21 survival rates from highest to lowest calculated inhaled dose of B. pseudomallei ATS2021 (960 CFU, 186 CFU, 21 CFU, 2 CFU, 0.4 CFU) as depicted in panel A are 0/10, 0/10, 1/10, 8/10, and 9/10. The day 60 survival rates as depicted in panel B are 0/10, 0/10, 1/10, 8/10, and 9/10.

Figure 5. Kaplan-Meier survival plots calculated for BALB/c mice exposed to aerosolized Burkholderia pseudomalleiATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the...

We used C57BL/6 mice because they are an accepted model for vaccine development (34,35). The LD50 estimate after exposure to aerosolized ATS2021 was ≈56 CFU after 21 days and 6 CFU after 60 days (Table, Figure 4). We also determined the LD50 in BALB/c mice because they are used for pathogenesis and therapeutic studies (19,33,36). The LD50 estimate for 21 and 60 days after exposure to aerosolized ATS2021 was ≈4 CFU for both time frames (Table, Figure 5). Those LD50 values categorize the isolate to be among the most virulent we have characterized. Retrospective statistical analyses supported this observation and demonstrated similar (p>0.1) virulence to B. pseudomallei strains 1026b, MSHR5855, HBPUB10303a, and HBPBUB10134a in C57BL/6 mice exposed to aerosolized bacteria (19). Clinical signs assumed to be associated with neurologic melioidosis were observed in some mice (e.g., uncoordinated and impaired movement, tremors, and hypersensitivity to touch).

Bacterial Burden in C57BL/6 Mice after Exposure to Aerosolized ATS2021

Figure 6

Serial sampling experiment to investigate bacterial dissemination in blood, spleens, and lungs of C57BL/6 mice at different challenge doses of aerosolized Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. C57BL/6 mice were estimated to have inhaled various doses on day 0. A subset of mice was then deeply anesthetized for a terminal blood collection, euthanized, and then the spleens and lungs were removed to determine the bacteriologic burden in each organ at each time point indicated. Bacterial counts are shown for whole blood (A–C), spleen homogenate (D–F), and lung homogenate (G–I). N = 4 for each time point. The CFU burden is shown for each mouse; the geometric mean is depicted with the horizontal bar. Limit of detection is ≈100 CFU/mL of blood and 5 CFU/organ.

Figure 6. Serial sampling experiment to investigate bacterial dissemination in blood, spleens, and lungs of C57BL/6 mice at different challenge doses of aerosolized Burkholderia pseudomalleistrain ATS2021, the causative strain in...

Figure 7

Serial sampling experiment to investigate bacterial dissemination in brains of C57BL/6 mice at different challenge doses of aerosolized Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. C57BL/6 mice were estimated to have inhaled various doses of aerosolized Burkholderia pseudomallei ATS2021 on day 0: A) 107 CFU, B) 1,150 CFU, and C) 4,490 CFU. A subset of mice was then deeply anesthetized for a terminal blood collection, euthanized, and then brains were removed to determine the bacteriologic burden in each brain at each time point indicated. N = 4 for each time point. The CFU burden is shown for each mouse, depicted as a black circle; geometric mean is depicted with the horizontal bar. The brain homogenates were exposed to ≈21 kGy of gamma radiation, proven sterile, and then subjected to the B. pseudomallei capsule-specific immunodiagnostic assay. The MFI of each mouse is depicted by a red circle, and the geometric mean is depicted with the horizontal bar. Limit of detection is ≈5 CFU/organ. The detection of capsule in the irradiated brain homogenate is depicted in red and is displayed as MFI. MFI, mean fluorescent intensity.

Figure 7. Serial sampling experiment to investigate bacterial dissemination in brains of C57BL/6 mice at different challenge doses of aerosolized Burkholderia pseudomalleistrain ATS2021, the causative strain in an an outbreak...

We performed a serial sampling experiment to investigate bacterial dissemination in C57BL/6 mice at different challenge doses (107 CFU, 1,150 CFU, and 4,490 CFU). Bacterial dissemination patterns depend on the dose of inhaled bacteria after aerosolization (Figure 6). The 2 highest inhaled doses resulted in early bacteremia (Figure 6, panels B, C). B. pseudomallei was detected in the spleens (Figure 6, panels D–F) of nearly all animals within 24 hours. Regardless of the exposure dose, all mice had substantial bacterial replication in the lungs within 24 hours, as expected, given that the lungs were the main portal of entry for the bacteria (Figure 6, panels G–I). We examined the brains and identified substantial bacterial burden within 24 hours after inhalation in the 3 doses (Figure 7, black data points). We also performed a capsule-specific immune-diagnostic assay on gamma-irradiated brain homogenates. Detection of capsule in those samples (Figure 7, red data points) was reflective of the bacterial burden, but quantification of viable bacteria via culture was more sensitive.

Representative Histopathology in C57BL/6 Mice after Inhalation of ATS2021

We performed histopathologic analyses on a subset of animals. Animals that died 1–3 days after aerosol exposure probably did not have time for substantial tissue lesions to develop (despite high exposure doses) and may have received lower severity scores because of rapid time to death or euthanasia, which accounts for the lowest animal scores at days 1, 2, and 3 in all 3 groups (Appendix 1 Table 1). Pathologic lesions in mice were consistent with lesions produced by other strains of B. pseudomallei (19,37). In general, the focal-to-coalescing necrotizing lesions were accompanied by many degenerate neutrophils and accumulating necrotic debris to form variably sized necrosuppurative lesions, which expand to form more organized abscesses with time.

Figure 8

Hematoxylin and eosin staining of head sections of C57BL/6 mice exposed to aerosolized Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. Shown are the nasal cavity (including nasal turbinates, nasal septum, respiratory and olfactory epithelium, lamina propria with supporting tissues and glands, nerve bundles, and nasal air passages); cribriform plate (bone and olfactory/trigeminal nerves); and cranial vault with olfactory bulb. A) Day 1 after exposure, dose 107 CFU, showing nasal turbinates (arrowhead), cribriform plate (asterisks), and olfactory bulb (arrow) that are essentially normal. Original magnification ×2. B) Day 2 after exposure, dose 4,490 CFU, showing mild necrosuppurative rhinitis (arrowheads) with edema, cellular debris and suppurative inflammation in few nasal air passages (arrows). Original magnification ×2. C) Day 3 after exposure, dose 4,490 CFU, showing multifocal moderate necrosuppurative rhinitis (arrowheads) and necrotizing and hemorrhagic meningoencephalitis of the olfactory bulb (arrows). Original magnification 2. D) Day 4 after exposure, dose 1,150 CFU. There is diffuse necrosuppurative rhinitis of the nasal turbinates (arrowheads), showing extensive necrosis and hemorrhage of the olfactory bulb with a small portion of recognizable neural tissue evident (arrow). Original magnification ×2.

Figure 8. Hematoxylin and eosin staining of head sections of C57BL/6 mice exposed to aerosolized Burkholderia pseudomalleistrain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of...

Figure 9

Histopathologic analyses of the neurologic system of C57BL/6 mice after inhalation of Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. A) Day 5 after exposure of group 4 mouse 45, dose 1,150 CFU. Cerebrum showing focally extensive necrotizing and hemorrhagic meningoencephalitis (arrowhead). Hematoxylin and eosin (HE) stain; original magnification ×2. B) Day 9 after exposure, dose 107 CFU. Pons and cerebellum. There is multifocal necrotizing meningoencephalitis (arrows). HE stain; original magnification ×2. C) Day 10 after exposure, dose 1,150 CFU. Cerebrum with olfactory peduncle filled with viable and degenerate neutrophils with no recognizable peduncular tissue (arrowhead). HE stain; original magnification ×20. D) Day 9 after exposure, 107 CFU. Spinal cord, thoracic, shows multifocal meningomyelitis (arrowheads). HE stain; original magnification ×4. E) Day 5 after exposure, 1,150 CFU. Spinal cord and vertebrae, lumbar at cauda equina, show is multifocal suppurative perineuritis of spinal nerves (arrows). Note the necrotizing lesion within the vertebral bone marrow (arrowhead) HE stain; original magnification ×10. F) Day 4 after exposure, dose 1,150 CFU. Spinal cord and vertebra, thoracic, show necrotizing osteomyelitis (arrowhead). Note the loss of distinction of bone marrow cells compared to normal cells of the bone marrow (arrow). HE stain; original magnification ×40.

Figure 9. Histopathologic analyses of the neurologic system of C57BL/6 mice after inhalation of Burkholderia pseudomalleistrain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them...

We prioritized the central nervous system to characterize the ATS2021 isolate after inhalation of small-particle aerosols (Figures 8,9). Lesions consistent with B. pseudomallei were seen by day 1 in the lung and nasal turbinates, the sites of initial colonization. Subsequently, lesions were noted by day 2 in the brain, specifically the olfactory bulb, and in the olfactory nerves of many mice from 1,150 and 4,490 CFU doses. In addition, by day 2, lesions were present in the spleen and liver, as noted by increased pathology scores (Appendix 1 Table 1). Lesions of the vertebral bone marrow were noted after 1,150 and 4,490 CFU doses within 3 days. Bone marrow lesions were primarily noted in the groups that received higher doses. Lesions of the cerebrum, cerebellum, and brainstem were noted by day 4 and spinal cord lesions by day 5 (Figure 9). Lesions were noted in the olfactory bulb in mice that received doses of 1,150 CFU and in the olfactory nerves of mice that received 1,150 CFU and 4,490 CFU within 48 hours after exposure and an increased the number of mice with lesions in the olfactory bulb by 36 hours.

Figure 10

Immunohistochemical analyses of head sections of C57BL/6 mice exposed to aerosolized Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. Shown are the nasal cavity (including nasal turbinates, nasal septum, respiratory and olfactory epithelium, lamina propria with supporting tissues and glands, nerve bundles, and nasal air passages); cribriform plate (bone and olfactory/trigeminal nerves); and cranial vault with olfactory bulb. A) Day 1 after exposure, dose 1,150 CFU, shows multifocal minimal positivity of the nasal cavity epithelium (arrowheads), which is most likely olfactory epithelium of the ethmoid turbinate. Original magnification ×2. B) Day 3 after exposure, dose 4,490 CFU, showing diffuse marked positivity of the nasal cavity epithelium (arrowhead) and multifocal moderate positivity of the olfactory bulb (arrows). Original magnification ×2. C) Day 6 after exposure, dose 107 CFU, showing diffuse severe positivity of the nasal cavity epithelium (arrowhead) and multifocal marked positivity of the olfactory bulb (arrow). Original magnification ×2. D) Day 4 after exposure, 1,150 CFU, showing diffuse severe positivity of the nasal cavity (arrowhead) and olfactory bulb (arrow). Originalmagnification ×2.

Figure 10. Immunohistochemical analyses of head sections of C57BL/6 mice exposed to aerosolized Burkholderia pseudomalleistrain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal,...

Figure 11

Immunohistochemical analyses of the neurologic system of C57BL/6 mice exposed to aerosolized Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. A) Day 6 after exposure, dose 107 CFU. Cerebrum shows multifocal moderate positivity (arrows). Original magnification ×2. B) Day 6 after exposure, dose 107 CFU. Cerebellum shows multifocal moderate positivity (arrow). Original magnification ×10. C) Day 5 after exposure, dose 1,150 CFU. Lumbar spinal cord at cauda equina and vertebra shows multifocal mild perineural positivity (arrows) of spinal nerves at cauda equina and marked vertebral bone marrow positivity (arrowheads). Original magnification ×10. D) Day 9 after exposure, dose 107 CFU. Spinal cord, cervical, shows focal moderate positivity (arrowheads). Original magnification ×20.

Figure 11. Immunohistochemical analyses of the neurologic system of C57BL/6 mice exposed to aerosolized Burkholderia pseudomalleistrain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them...

We performed IHC to support histopathologic findings and provide additional evidence that the lesions resulted from infection with B. pseudomallei (Appendix 1 Table 2). IHC clearly identified bone marrow lesions that are difficult to appreciate with hematoxylin and eosin staining. Nasal turbinates showed Burkholderia positivity by IHC within 24 hours after exposure, and IHC positivity was found within 48 hours in the mice receiving the highest inhaled dose in the brain olfactory bulb, olfactory nerves, and nasal turbinates (Figures 10,11).

Effects on Oligodendrocytes

Figure 12

Profiling of differentially expressed genes revealing downregulation of markers associated with oligodendrocytes after exposure to aerosolized Burkholderia pseudomallei strain ATS2021, the causative strain in an an outbreak of 4 cases, 2 of them fatal, in the United States in 2021. A) Significant downregulation or decreased expression of genes involved in oligodendrocyte function was observed in select challenge groups of mice on days 1,3, and 5 after challenge. Values are normalized to unchallenged control mice and represent 4 mice per group. Significance based on a 2-way analysis of variance. Error bars indicate 95% CIs. B) Heat map of differentially expressed genes associated with NanoString oligodendrocyte cell profiler panel (https://nanostring.com). Fold change is linear, and dots indicate gene changes that were above the significance threshold. C) Expression changes over time in select genes associated with oligodendrocyte function for the 1,150 CFU challenge group. In panels A and C, error bars represent standard deviation.

Figure 12. Profiling of differentially expressed genes revealing downregulation of markers associated with oligodendrocytes after exposure to aerosolized Burkholderia pseudomalleistrain ATS2021, the causative strain in an an outbreak of 4...

We applied a transcriptomic approach targeted against a range of neuroinflammatory genes in brain homogenates from mice. According to targeted expression levels, we used a cell profiling module to identify changes in neuronal cell types based on relative abundance of marker genes associated with oligodendrocytes. In the 2 highest dose groups, we observed statistically significant drops in oligodendrocyte signatures, particularly on days 3 and 5 (Figure 12, panel A). A total of 27 genes constitute the oligodendrocyte cell profile, of which 23 had significant expression differences for >1 time point (Figure 12, panel B). Total numbers of significant genes were dependent on infectious dose with no differential gene expression observed in the 107 CFU group. We observed early and pronounced down-regulation of many of these genes, as early as day 1 in the 4,490 CFU group. Of the 27 genes, 6 are known to predominately constitute the oligodendrocyte cell profile and all encode proteins involved in myelination or lipid metabolism (Appendix 2 Table). All 6 of the signatures were significantly down-regulated, further suggesting dysregulation in oligodendrocytes in infected hosts (Figure 12, panel C).

Discussion

Knowledge of the diversity of virulence associated with distinct geographic isolates of B. pseudomallei is crucial to the further development, testing, and evaluation of medical countermeasures. We characterized several factors that may contribute to the virulence associated with ATS2021. We examined several key genetic virulence attributes of that strain and demonstrated considerable virulence in 2 mouse models of inhalational melioidosis. Because ATS2021 was shown to carry the bimABm allele and neurologic involvement of this strain played a role in human infections, we focused on analyzing the histopathology associated with the rapid neurologic invasion. The nasal turbinates were heavily colonized within the first day after exposure to aerosolized bacteria, leading to infection of the olfactory bulb by day 2; the cerebrum, cerebellum, and brain stem by day 4; and the spinal column by day 5 (with evidence of infection in vertebral bone marrow within 3 days for mice inhaling the highest dose of aerosolized bacteria).

RNA analyses indicated that the oligodendrocyte populations in the infected mouse brains were significantly affected by the infection in a dose- and time-dependent manner. The robust decreases in oligodendrocyte abundance, function, or both that we observed in the highest bacterial challenge groups (Figure 12, panels A, B) suggest pronounced impairment of a glial cell population that is critical for brain homeostasis and function. Oligodendrocytes are responsible for myelination of the CNS, encapsulating neuronal axons in lipid-rich membranes that serve as insulators enabling rapid neuronal conduction (38,39). Given the role of oligodendrocytes in brain function, a variety of neurodegenerative disorders affecting the brain and spinal cord are associated with demyelination (e.g., multiple sclerosis) (40,41). There are known microbial-associated causes of oligodendrocyte dysfunction and associated demyelination; progressive multifocal leukoencephalopathy is caused by infection of oligodendrocytes by the JC virus (42), and Borrelia burgdorferi can induce oligodendrocyte apoptosis (43). Although more study is needed, the down-regulation of genes associated with myelination could account for some of the clinical signs observed in mice and nonhuman primates when infected with neurotropic strains of B. pseudomallei, including muscle weakness, tremors, and extreme sensitivity to touch (37,44).

Last, we are intrigued by the robust biofilm production at 37°C compared with other strains of B. pseudomallei. Although virulence (assayed by an intraperitoneal BALB/c infection model) did not correlate with biofilm production of B. pseudomallei isolates from Thailand (45), biofilm formation is associated with virulence of other bacteria (46,47). That this biofilm phenotype is exaggerated at 37°C suggests a potential role in pathogenesis that may be relevant to inhaled B. pseudomallei in the context of colonization of upper respiratory areas (e.g., nasal turbinates as the result of inhaling the bacteria) and may contribute to the intrinsic difficulty in successfully treating melioidosis with antimicrobial drugs (48). Our retrospective analyses support the data published by Taweechaisupapong et al., which demonstrate no correlation between biofilm formation and virulence associated with intraperitoneal injection (45), but we did identify a statistically significant negative correlation between in vitro biofilm formation and virulence as measured by mouse models of inhalational melioidosis. Future work focused on identifying correlations between biofilm formation and neurologic melioidosis should help clarify the effect of host–bacterial interactions on CNS demyelination.

Combined, our data, previous case-reports (11,12), and the identification of endemic strains in Mississippi (49) support the idea that melioidosis is an emerging infectious disease in the United States. Thus, it is imperative that we understand the new isolates in the context of inhalational and neurologic melioidosis to accurately predict the hazards associated with this emerging pathogen for the biodefense and public health communities. Clinical laboratories must continue to be on the alert for melioidosis within the United States, and new isolates should be used to develop and test novel medical countermeasures and diagnostic strategies.

Dr. Cote is the deputy chief of the Bacteriology Division at the US Army Medical Research Institute of Infectious Diseases. His interests are high-containment bacteriologic research to include medical countermeasure development, bacterial pathogenesis, and animal models of bacterial diseases.

Top

Acknowledgment

Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the US Army, the US Defense Health Agency, or the Centers for Disease Control and Prevention. Research was conducted under an animal care and use protocol approved by the US Army Medical Research Institute of Infectious Diseases Institutional Animal Care and Use Committee in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.

Top

References

  1. Currie  BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med. 2015;36:111–25. DOIPubMedGoogle Scholar
  2. Currie  BJ, Meumann  EM, Kaestli  M. The expanding global footprint of Burkholderia pseudomallei and melioidosis. Am J Trop Med Hyg. 2023;108:1081–3. DOIPubMedGoogle Scholar
  3. Chantratita  N, Phunpang  R, Yarasai  A, Dulsuk  A, Yimthin  T, Onofrey  LA, et al. Characteristics and one year outcomes of melioidosis patients in northeastern Thailand: a prospective, multicenter cohort study. Lancet Reg Health Southeast Asia. 2023;9:9. DOIPubMedGoogle Scholar
  4. Currie  BJ, Mayo  M, Ward  LM, Kaestli  M, Meumann  EM, Webb  JR, et al. The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. Lancet Infect Dis. 2021;21:1737–46. DOIPubMedGoogle Scholar
  5. Currie  BJ, Fisher  DA, Howard  DM, Burrow  JN. Neurological melioidosis. Acta Trop. 2000;74:145–51. DOIPubMedGoogle Scholar
  6. Wongwandee  M, Linasmita  P. Central nervous system melioidosis: A systematic review of individual participant data of case reports and case series. PLoS Negl Trop Dis. 2019;13:e0007320. DOIPubMedGoogle Scholar
  7. Sullivan  RP, Marshall  CS, Anstey  NM, Ward  L, Currie  BJ. 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl Trop Dis. 2020;14:e0008659. DOIPubMedGoogle Scholar
  8. Gora  H, Hasan  T, Smith  S, Wilson  I, Mayo  M, Woerle  C, et al. Melioidosis of the central nervous system; impact of the bimABm allele on patient presentation and outcome. Clin Infect Dis. 2022;•••:ciac111.PubMedGoogle Scholar
  9. Mukhopadhyay  C, Kaestli  M, Vandana  KE, Sushma  K, Mayo  M, Richardson  L, et al. Molecular characterization of clinical Burkholderia pseudomallei isolates from India. Am J Trop Med Hyg. 2011;85:121–3. DOIPubMedGoogle Scholar
  10. Limmathurotsakul  D, Dance  DA, Wuthiekanun  V, Kaestli  M, Mayo  M, Warner  J, et al. Systematic review and consensus guidelines for environmental sampling of Burkholderia pseudomallei. PLoS Negl Trop Dis. 2013;7:e2105. DOIPubMedGoogle Scholar
  11. Gee  JE, Bower  WA, Kunkel  A, Petras  J, Gettings  J, Bye  M, et al. Multistate outbreak of melioidosis associated with imported aromatherapy spray. N Engl J Med. 2022;386:861–8. DOIPubMedGoogle Scholar
  12. Petras  JK, Elrod  MG, Ty  M, Adams  P, Zahner  D, Adams  A, et al. Notes from the field: Burkholderia pseudomallei detected in a raccoon carcass linked to a multistate aromatherapy-associated melioidosis outbreak—Texas, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1597–8. DOIPubMedGoogle Scholar
  13. Matthews  RJ, Smith  S, Wilson  I, Tjahjono  R, Young  S, Hanson  J. Case report: vagal nerve neuritis associated with pulmonary melioidosis provides potential insights into the pathophysiology of neuromelioidosis. Am J Trop Med Hyg. 2023;108:1212–4. DOIPubMedGoogle Scholar
  14. St John  JA, Walkden  H, Nazareth  L, Beagley  KW, Ulett  GC, Batzloff  MR, et al. Burkholderia pseudomallei rapidly infects the brain stem and spinal cord via the trigeminal nerve after intranasal inoculation. Infect Immun. 2016;84:2681–8. DOIPubMedGoogle Scholar
  15. Walkden  H, Delbaz  A, Nazareth  L, Batzloff  M, Shelper  T, Beacham  IR, et al. Burkholderia pseudomallei invades the olfactory nerve and bulb after epithelial injury in mice and causes the formation of multinucleated giant glial cells in vitro. PLoS Negl Trop Dis. 2020;14:e0008017. DOIPubMedGoogle Scholar
  16. St John  JA, Ekberg  JA, Dando  SJ, Meedeniya  AC, Horton  RE, Batzloff  M, et al. Burkholderia pseudomallei penetrates the brain via destruction of the olfactory and trigeminal nerves: implications for the pathogenesis of neurological melioidosis. MBio. 2014;5:e00025. DOIPubMedGoogle Scholar
  17. Burnard  D, Bauer  MJ, Falconer  C, Gassiep  I, Norton  RE, Paterson  DL, et al. Clinical Burkholderia pseudomallei isolates from north Queensland carry diverse bimABm genes that are associated with central nervous system disease and are phylogenomically distinct from other Australian strains. PLoS Negl Trop Dis. 2022;16:e0009482. DOIPubMedGoogle Scholar
  18. Sarovich  DS, Price  EP, Webb  JR, Ward  LM, Voutsinos  MY, Tuanyok  A, et al. Variable virulence factors in Burkholderia pseudomallei (melioidosis) associated with human disease. PLoS One. 2014;9:e91682. DOIPubMedGoogle Scholar
  19. Trevino  SR, Klimko  CP, Reed  MC, Aponte-Cuadrado  MJ, Hunter  M, Shoe  JL, et al. Disease progression in mice exposed to low-doses of aerosolized clinical isolates of Burkholderia pseudomallei. PLoS One. 2018;13:e0208277. DOIPubMedGoogle Scholar
  20. Guyton  AC. Measurement of the respiratory volumes of laboratory animals. Am J Physiol. 1947;150:70–7. DOIPubMedGoogle Scholar
  21. Marchetti  R, Dillon  MJ, Burtnick  MN, Hubbard  MA, Kenfack  MT, Blériot  Y, et al. Burkholderia pseudomallei capsular polysaccharide recognition by a monoclonal antibody reveals key details toward a biodefense vaccine and diagnostics against melioidosis. ACS Chem Biol. 2015;10:2295–302. DOIPubMedGoogle Scholar
  22. Stefan  CP, Arnold  CE, Shoemaker  CJ, Zumbrun  EE, Altamura  LA, Douglas  CE, et al. Transcriptomic analysis reveals host miRNAs correlated with immune gene dysregulation during fatal disease progression in the Ebola virus cynomolgus macaque disease model. Microorganisms. 2021;9:665. DOIPubMedGoogle Scholar
  23. Perkins  JR, Dawes  JM, McMahon  SB, Bennett  DL, Orengo  C, Kohl  M. ReadqPCR and NormqPCR: R packages for the reading, quality checking and normalisation of RT-qPCR quantification cycle (Cq) data. BMC Genomics. 2012;13:296. DOIPubMedGoogle Scholar
  24. Reckseidler  SL, DeShazer  D, Sokol  PA, Woods  DE. Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun. 2001;69:34–44. DOIPubMedGoogle Scholar
  25. DeShazer  D, Brett  PJ, Woods  DE. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol. 1998;30:1081–100. DOIPubMedGoogle Scholar
  26. Burtnick  MN, Brett  PJ, Harding  SV, Ngugi  SA, Ribot  WJ, Chantratita  N, et al. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun. 2011;79:1512–25. DOIPubMedGoogle Scholar
  27. Holden  MT, Titball  RW, Peacock  SJ, Cerdeño-Tárraga  AM, Atkins  T, Crossman  LC, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2004;101:14240–5. DOIPubMedGoogle Scholar
  28. Benanti  EL, Nguyen  CM, Welch  MD. Virulent Burkholderia species mimic host actin polymerases to drive actin-based motility. Cell. 2015;161:348–60. DOIPubMedGoogle Scholar
  29. Morris  JL, Fane  A, Sarovich  DS, Price  EP, Rush  CM, Govan  BL, et al. Increased neurotropic threat from Burkholderia pseudomallei strains with a B. mallei–like variation in the bimA motility gene, Australia. Emerg Infect Dis. 2017;23:740–9. DOIPubMedGoogle Scholar
  30. Sitthidet  C, Stevens  JM, Chantratita  N, Currie  BJ, Peacock  SJ, Korbsrisate  S, et al. Prevalence and sequence diversity of a factor required for actin-based motility in natural populations of Burkholderia species. J Clin Microbiol. 2008;46:2418–22. DOIPubMedGoogle Scholar
  31. Jayasinghearachchi  HS, Corea  EM, Jayaratne  KI, Fonseka  RA, Muthugama  TA, Masakorala  J, et al. Biogeography and genetic diversity of clinical isolates of Burkholderia pseudomallei in Sri Lanka. PLoS Negl Trop Dis. 2021;15:e0009917. DOIPubMedGoogle Scholar
  32. Janesomboon  S, Muangsombut  V, Srinon  V, Meethai  C, Tharinjaroen  CS, Amornchai  P, et al. Detection and differentiation of Burkholderia species with pathogenic potential in environmental soil samples. PLoS One. 2021;16:e0245175. DOIPubMedGoogle Scholar
  33. Welkos  SL, Klimko  CP, Kern  SJ, Bearss  JJ, Bozue  JA, Bernhards  RC, et al. Characterization of Burkholderia pseudomallei strains using a murine intraperitoneal infection model and in vitro macrophage assays. PLoS One. 2015;10:e0124667. DOIPubMedGoogle Scholar
  34. Limmathurotsakul  D, Funnell  SG, Torres  AG, Morici  LA, Brett  PJ, Dunachie  S, et al.; Steering Group on Melioidosis Vaccine Development. Consensus on the development of vaccines against naturally acquired melioidosis. Emerg Infect Dis. 2015;21:e141480. DOIPubMedGoogle Scholar
  35. Conejero  L, Patel  N, de Reynal  M, Oberdorf  S, Prior  J, Felgner  PL, et al. Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis. Am J Pathol. 2011;179:270–80. DOIPubMedGoogle Scholar
  36. Nelson  M, Barnes  KB, Davies  CH, Cote  CK, Meinig  JM, Biryukov  SS, et al. The BALB/c mouse model for the evaluation of therapies to treat infections with aerosolized Burkholderia pseudomallei. Antibiotics (Basel). 2023;12:506. DOIPubMedGoogle Scholar
  37. Bearss  JJ, Hunter  M, Dankmeyer  JL, Fritts  KA, Klimko  CP, Weaver  CH, et al. Characterization of pathogenesis of and immune response to Burkholderia pseudomallei K96243 using both inhalational and intraperitoneal infection models in BALB/c and C57BL/6 mice. PLoS One. 2017;12:e0172627. DOIPubMedGoogle Scholar
  38. Stassart  RM, Möbius  W, Nave  KA, Edgar  JM. The axon-myelin unit in development and degenerative disease. Front Neurosci. 2018;12:467. DOIPubMedGoogle Scholar
  39. Molina-Gonzalez  I, Miron  VE, Antel  JP. Chronic oligodendrocyte injury in central nervous system pathologies. Commun Biol. 2022;5:1274. DOIPubMedGoogle Scholar
  40. Kenigsbuch  M, Bost  P, Halevi  S, Chang  Y, Chen  S, Ma  Q, et al. A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci. 2022;25:876–86. DOIPubMedGoogle Scholar
  41. Graf  LM, Rosenkranz  SC, Hölzemer  A, Hagel  C, Goebell  E, Jordan  S, et al. Clinical presentation and disease course of 37 consecutive cases of progressive multifocal leukoencephalopathy (PML) at a German tertiary-care hospital: a retrospective observational study. Front Neurol. 2021;12:632535. DOIPubMedGoogle Scholar
  42. Cortese  I, Reich  DS, Nath  A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17:37–51. DOIPubMedGoogle Scholar
  43. Ramesh  G, Borda  JT, Dufour  J, Kaushal  D, Ramamoorthy  R, Lackner  AA, et al. Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis. Am J Pathol. 2008;173:1415–27. DOIPubMedGoogle Scholar
  44. Trevino  SR, Dankmeyer  JL, Fetterer  DP, Klimko  CP, Raymond  JLW, Moreau  AM, et al. Comparative virulence of three different strains of Burkholderia pseudomallei in an aerosol non-human primate model. PLoS Negl Trop Dis. 2021;15:e0009125. DOIPubMedGoogle Scholar
  45. Taweechaisupapong  S, Kaewpa  C, Arunyanart  C, Kanla  P, Homchampa  P, Sirisinha  S, et al. Virulence of Burkholderia pseudomallei does not correlate with biofilm formation. Microb Pathog. 2005;39:77–85. DOIPubMedGoogle Scholar
  46. Boisvert  AA, Cheng  MP, Sheppard  DC, Nguyen  D. Microbial biofilms in pulmonary and critical care diseases. Ann Am Thorac Soc. 2016;13:1615–23. DOIPubMedGoogle Scholar
  47. Chakraborty  P, Bajeli  S, Kaushal  D, Radotra  BD, Kumar  A. Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. Nat Commun. 2021;12:1606. DOIPubMedGoogle Scholar
  48. Nyanasegran  PK, Nathan  S, Firdaus-Raih  M, Muhammad  NAN, Ng  CL. Biofilm signaling, composition and regulation in Burkholderia pseudomallei. J Microbiol Biotechnol. 2023;33:15–27. DOIPubMedGoogle Scholar
  49. Petras  JK, Elrod  MG, Ty  MC, Dawson  P, O’Laughlin  K, Gee  JE, et al. Locally acquired melioidosis linked to environment—Mississippi, 2020–2023. N Engl J Med. 2023;389:2355–62. DOIPubMedGoogle Scholar

Top

Figures
Table

Top

Suggested citation for this article: Cote CK, Mlynek KD, Klimko CP, Biryukov SS, Mou S, Hunter M, et al. Virulence of Burkholderia pseudomallei ATS2021 unintentionally imported to United States in aromatherapy spray. Emerg Infect Dis. 2024 Oct [date cited]. https://doi.org/10.3201/eid3010.240084

DOI: 10.3201/eid3010.240084

Original Publication Date: September 11, 2024

Table of Contents – Volume 30, Number 10—October 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Christopher K. Cote and David DeShazer, US Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 1425 Porter St, Fort Detrick, Frederick, MD 21702; USA

Send To

10000 character(s) remaining.

Top

Page created: September 11, 2024
Page updated: September 11, 2024
Page reviewed: September 11, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external